skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: What stocks would you look at to profit from the respiratory virus which is showing up in China right now? Thank you.

Jason
Read Answer Asked by Jason on January 20, 2020
Q: Hello Peter and Team,
Wondering if you think this may be a good entry point for an investment in Greenbrook TMS. The company claims that its electromagnetic treatment for clinical depression is 68% effective with no significant side effects. This would make it more effective than any single depression drug on the market. With depression being so prevalent and insurance companies looking to save LTD payouts, it seems likely that the popularity of this treatment modality could quickly become widespread. Although it may be an effective treatment, what do you think of the company’s business model?
Thank you.
Brad
Read Answer Asked by Bradley on January 17, 2020
Q: On several occasions when responding to questions about WELL you mention risk - an excellent point as it is a relatively small company. 

But in comparison to many other smaller companies there are important aspects that in my mind mitigate the risk somewhat. For example:

- the quality and reputation of management and its obvious ability to attract investors

- founded first and foremost on the ownership of health clinics (relatively stable recurring revenue, insulated somewhat from recessions)

- disciplined/focused in its choice of foundational corporate software platform (i.e. OSCAR).  OSCAR is open source and free of royalties - think of RedHat's success.  OSCAR is its singular software focus - think Westjet and the cost savings by limiting maintenance to only one type of  aircraft. And then the cost/effort when it comes to adding new functionality (e.g. telemedicine) to your product like all software products must do. 

None of this guarantees unqualified success in the marketplace of course but what additional risks should an investor in WELL consider?   Thank you.  
Read Answer Asked by Richard on January 16, 2020
Q: Could you please give me a couple of suggestions for US Healthcare stocks. will be held in a RRSP account. I only have Guardant (Small position) at the moment. Thanks
Read Answer Asked by Rudy on January 13, 2020
Q: Another service really likes fertility company Hamilton Thorne and has made it a recommendation. Progyny in the US seems to be doing well in a related business so I wanted your thoughts. With people marrying later the theme seems to make sense. Do you like it? A brief example of the write is up below. They write interesting stuff but don't have your track record so I'd love to know what 5i thinks.

When we recommended Hamilton Thorne back in August, we believed the strategy for growth was three-pronged, involving both acquisitions and organic opportunity as well as margin improvement along the way. Recent results fully support our belief, and we’re firmly of the mind that we’re nicely on track.
Read Answer Asked by Tim on January 13, 2020
Q: Hello again, 5i team. Thinking about initiating a small postion (1.5% of overall portfolio) in this stock, likely for my TFSA. Stock is up 378% in the last 30 days (!), but I'm having trouble determing whether or not the jump is based on anything substantive. I would greatly appreciate your views on the company itself and the stock in the next 6 - 12 months. Thanks for all the great insights. - Asher
Read Answer Asked by Asher on January 13, 2020
Q: Hi 5i team!

What is your opinion of HLS these days?
I last asked about them in Feb 2019. At the time you were concerned about their debt level. Has it improved (marginally or otherwise) since then or do you foresee any further improvement in 2020 and beyond based on their recent financials?
They had a good 2019 wrt stock price appreciation.
They have recently received approval from Health Canada re Vascepa but significant sales from that drug may not occur for a year or 2 (or more).
Can this be added to an already diversified portfolio of mid caps? I recently took a 1/4 position in mid Dec at $19.34. I would like to add a further 1/4 position each quarter going forward. This will allow me to monitor their overall progress wrt their additional drug portfolio.
They stated that peak sales of Vascepa may not occur until 2-4 years thus the patient accumulation.

Cheers,
Steve
Read Answer Asked by Stephen on January 09, 2020
Q: Which US and Canadian healthcare names would you be comfortable initiating a position in today?
Read Answer Asked by Patrick on January 08, 2020
Q: I am not clear on your December 23 comment on Gilead. You write that GILD has (or may have been) a “value trap” . You do not say whether your view is to sell. Is it your thinking that GILD is a hold? Or did you mean to say it is likely better to sell GILD? I am not sure how 5i defines value trap and you did not elaborate. One acknowledges that your comments are not advice.... that’s understood. With that in mind, I would appreciate more clarity on your thinking. Several pharma and bio tech companies are frustrating securities to hold. But sometimes the pipeline or prospects make the risk-reward equation such that patience is advised. Is it here?
Read Answer Asked by Adam on January 08, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!